Considering that LARS1 is overexpressed in some cancers, including myeloid leukemia93, pancreatic cancer, renal cancer, cervical cancer and skin cancer (Fig. 3), targeting the leucine-sensing-mediated function of LARS1 has therapeutic potential against cancer. This evidence concerns the gene LARS1 and renal carcinoma.